Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.70 |
| ▸ | PPARA | Q07869 | 16/20 | 0.70 |
| ▸ | PPARD | Q03181 | 9/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10367150 | 0.92 | PPARG (0.64) | PPARGPPARAPPARD | |
| SCHEMBL5125360 | 0.86 | PPARA (0.83) | PPARGPPARAPPARD | |
| SCHEMBL6970427 | 0.86 | PPARG (0.64) | PPARGPPARAPPARD | |
| SCHEMBL10366934 | 0.86 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL4389208 | 0.85 | PPARG (0.79) | PPARGPPARAPPARD | |
| SCHEMBL10681829 | 0.85 | PPARG (0.51) | PPARGPPARAPPARD | |
| SCHEMBL3283978 | 0.84 | PPARG (0.77) | PPARGPPARAPPARD | |
| SCHEMBL5098728 | 0.83 | PPARG (0.76) | PPARGPPARAPPARD | |
| SCHEMBL10365776 | 0.83 | MEN1 (0.48) | PPARGPPARAPPARD | |
| SCHEMBL5110945 | 0.82 | PPARG (1.00) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6414001-B2 | Ether and amide compounds preparation thereof composition containing same and use thereof as antidiadetics | KOTOBUKI PHARMACEUTICAL CO. LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| US-20010008898-A1 | Ether and amide compounds and preparation of thereof as antidiadetics. | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2001-07-19 | — | — | US | disclosed |
| US-6214842-B1 | TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA TYPICALLY ASSOCIATED WITH OBESITY OR GLUCOSE INTOLERANCE; TREATING DIABETES TYPES I AND II | WYETH | 2001-04-10 | — | — | US | disclosed |
| EP-0177353-B1 | THIAZOLIDINEDIONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-04-11 | — | — | EP | disclosed |
| US-4725610-A | TREATMENT OF HYPERLIPEMIA AND DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| EP-0177353-A2 | Thiazolidinedione derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008898-A1 | Ether and amide compounds and preparation of thereof as antidiadetics. | SLC5A2, GCG, NCEH1 | PPARG 428/4885PPARA 404/4885PPARD 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.